Positive News SentimentPositive NewsNASDAQ:AMED Amedisys (AMED) Stock Price, News & Analysis → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free AMED Stock Alerts $96.30 +0.17 (+0.18%) (As of 12:21 PM ET) Add Compare Share Share Today's Range$95.85▼$96.6050-Day Range$90.40▼$96.1352-Week Range$74.61▼$96.60Volume74,636 shsAverage Volume272,414 shsMarket Capitalization$3.15 billionP/E RatioN/ADividend YieldN/APrice Target$100.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Amedisys alerts: Email Address Amedisys MarketRank™ Stock AnalysisAnalyst RatingHold2.13 Rating ScoreUpside/Downside4.7% Upside$100.80 Price TargetShort InterestBearish7.25% of Float Sold ShortDividend StrengthN/ASustainability-0.61Upright™ Environmental ScoreNews Sentiment1.70Based on 4 Articles This WeekInsider TradingN/AProj. Earnings Growth8.97%From $4.57 to $4.98 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.93 out of 5 starsMedical Sector415th out of 918 stocksHome Health Care Services Industry7th out of 8 stocks 1.1 Analyst's Opinion Consensus RatingAmedisys has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageAmedisys has only been the subject of 3 research reports in the past 90 days.Read more about Amedisys' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.25% of the float of Amedisys has been sold short.Short Interest Ratio / Days to CoverAmedisys has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Amedisys has recently decreased by 3.35%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAmedisys does not currently pay a dividend.Dividend GrowthAmedisys does not have a long track record of dividend growth. Previous Next 5.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmedisys has received a 82.47% net impact score from Upright. Amedisys seems to create the most significant positive value in categories "Jobs", "Meaning & joy", and "Taxes". The positive contribution in the "Meaning & joy" impact category is mostly driven by its "Private hospice care", "Private speech therapy services", and "Private occupational physiotherapy services" products. See details.Environmental SustainabilityThe Environmental Impact score for Amedisys is -0.61. Previous Next 3.2 News and Social Media Coverage News SentimentAmedisys has a news sentiment score of 1.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Amedisys this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for AMED on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amedisys insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Amedisys is held by insiders.Percentage Held by Institutions94.36% of the stock of Amedisys is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amedisys' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Amedisys are expected to grow by 8.97% in the coming year, from $4.57 to $4.98 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amedisys is -150.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amedisys is -150.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioAmedisys has a PEG Ratio of 3.51. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmedisys has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Amedisys' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. About Amedisys Stock (NASDAQ:AMED)Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.Read More AMED Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMED Stock News HeadlinesMay 20 at 8:45 PM | msn.comAmedisys gains amid report about status of DOJ review of UnitedHealth dealMay 8, 2024 | msn.comAmedisys gains amid report of sweetened divestiture offer in UnitedHealth dealMay 7, 2024 | fool.comAmedisys (NASDAQ: AMED)May 1, 2024 | finance.yahoo.comAmedisys, Inc. (AMED)April 30, 2024 | msn.comUnitedHealth grew very big. Now, some lawmakers want to chop it down.April 25, 2024 | finanznachrichten.deAmedisys, Inc.: Amedisys Reports First Quarter 2024 Financial ResultsApril 25, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Hold Rating on Amedisys (AMED)April 25, 2024 | sfgate.comAmedisys: Q1 Earnings SnapshotApril 25, 2024 | investorplace.comAMED Stock Earnings: Amedisys Beats EPS, Beats Revenue for Q1 2024April 24, 2024 | globenewswire.comAmedisys Reports First Quarter 2024 Financial ResultsApril 19, 2024 | msn.comDOJ case against UnitedHealth could take years to resolve, says BoAApril 19, 2024 | finance.yahoo.comInterim HealthCare Appoints New Clinical Quality LeaderApril 11, 2024 | msn.comImpact of aldehydes on DNA damage and agingApril 3, 2024 | finance.yahoo.comSurescripts exploring a sale: reportMarch 25, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Amedisys (AMED) and Masimo (MASI)March 25, 2024 | msn.comUnitedHealth's Takeover of Amedisys Expected to Close Despite Potential Regulatory Hurdles, RBC SaysMarch 20, 2024 | msn.comAmedisys dips amid report DOJ considering lawsuit to block UnitedHealth dealMarch 19, 2024 | reuters.comOregon's health authority reviewing UnitedHealth's acquisition of AmedisysFebruary 24, 2024 | finance.yahoo.comCAH Mar 2024 103.000 putFebruary 23, 2024 | finanznachrichten.deAmedisys, Inc.: Amedisys Reports Fourth Quarter and Year-End 2023 Financial ResultsFebruary 23, 2024 | uk.finance.yahoo.comQ4 2023 Blue Owl Capital Corp Earnings CallFebruary 22, 2024 | finance.yahoo.comAmedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to SayFebruary 21, 2024 | msn.comAmedisys (AMED) Q4 Earnings Lag EstimatesFebruary 21, 2024 | finance.yahoo.comAmedisys Reports Fourth Quarter and Year-End 2023 Financial ResultsFebruary 21, 2024 | finance.yahoo.comAmedisys Inc (AMED) Reports Mixed Results Amidst Merger TransactionsSee More Headlines Receive AMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/24/2024Today5/21/2024Next Earnings (Estimated)7/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Home health care services Sub-IndustryHealth Care Services Current SymbolNASDAQ:AMED CUSIP02343610 CIK896262 Webwww.amedisys.com Phone(225) 292-2031Fax225-292-8163Employees19,000Year Founded1982Price Target and Rating Average Stock Price Target$100.80 High Stock Price Target$101.00 Low Stock Price Target$100.00 Potential Upside/Downside+4.7%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E Ratio21.07 P/E Growth3.51Net Income$-9,750,000.00 Net Margins-0.91% Pretax Margin1.43% Return on Equity12.85% Return on Assets6.95% Debt Debt-to-Equity Ratio0.31 Current Ratio1.09 Quick Ratio1.09 Sales & Book Value Annual Sales$2.24 billion Price / Sales1.41 Cash Flow$6.23 per share Price / Cash Flow15.45 Book Value$34.31 per share Price / Book2.81Miscellaneous Outstanding Shares32,680,000Free Float32,089,000Market Cap$3.15 billion OptionableOptionable Beta0.84 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMs. Allyson GuidrozChief Accounting Officer & Principal Accounting OfficerMs. Jennifer Guckert GriffinSenior VP, Deputy General Counsel, Corporate Secretary & Interim Chief Legal OfficerKendra KimmonsVP of Marketing & Communications & Media RelationsMr. Adam Holton (Age 53)Chief People Officer Mr. Francis MayerSenior Vice President of DevelopmentKey CompetitorsLHC GroupNASDAQ:LHCGChemedNYSE:CHEBrightSpring Health ServicesNASDAQ:BTSGAddus HomeCareNASDAQ:ADUSAdaptHealthNASDAQ:AHCOView All CompetitorsInstitutional OwnershipWalleye Trading LLCSold 2,000 shares on 5/17/2024Ownership: 0.000%Comerica BankSold 555 shares on 5/17/2024Ownership: 0.040%Janus Henderson Group PLCSold 83,985 shares on 5/16/2024Ownership: 0.874%Murchinson Ltd.Bought 73,263 shares on 5/16/2024Ownership: 0.224%California State Teachers Retirement SystemBought 21,671 shares on 5/16/2024Ownership: 0.167%View All Institutional Transactions AMED Stock Analysis - Frequently Asked Questions Should I buy or sell Amedisys stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares. View AMED analyst ratings or view top-rated stocks. What is Amedisys' stock price target for 2024? 8 brokerages have issued 12-month price objectives for Amedisys' shares. Their AMED share price targets range from $100.00 to $101.00. On average, they expect the company's stock price to reach $100.80 in the next twelve months. This suggests a possible upside of 4.7% from the stock's current price. View analysts price targets for AMED or view top-rated stocks among Wall Street analysts. How have AMED shares performed in 2024? Amedisys' stock was trading at $95.06 at the beginning of 2024. Since then, AMED shares have increased by 1.3% and is now trading at $96.30. View the best growth stocks for 2024 here. When is Amedisys' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 24th 2024. View our AMED earnings forecast. How were Amedisys' earnings last quarter? Amedisys, Inc. (NASDAQ:AMED) issued its quarterly earnings data on Wednesday, April, 24th. The health services provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. The health services provider had revenue of $571.41 million for the quarter, compared to analysts' expectations of $565.38 million. Amedisys had a negative net margin of 0.91% and a positive trailing twelve-month return on equity of 12.85%. Amedisys's revenue for the quarter was up 2.7% on a year-over-year basis. During the same period last year, the business posted $1.00 EPS. What ETFs hold Amedisys' stock? ETFs with the largest weight of Amedisys (NASDAQ:AMED) stock in their portfolio include First Trust Merger Arbitrage ETF (MARB), IQ Merger Arbitrage ETF (MNA), SPDR S&P Health Care Services ETF (XHS), AltShares Event-Driven ET (EVNT), AltShares Merger Arbitrage ETF (ARB), Sovereigns Capital Flourish Fund (SOVF) and Fundamentals First ETF (KNOW).iShares U.S. Healthcare Providers ETF (IHF). What is Paul B. Kusserow's approval rating as Amedisys' CEO? 478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend. What other stocks do shareholders of Amedisys own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD). Who are Amedisys' major shareholders? Amedisys' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.49%), Janus Henderson Group PLC (0.87%), Gabelli Funds LLC (0.68%), GABELLI & Co INVESTMENT ADVISERS INC. (0.60%), Principal Financial Group Inc. (0.38%) and Natixis (0.33%). Insiders that own company stock include Bruce D Perkins, Christopher Gerard, David L Kemmerly, Denise M Bohnert, Michael Paul North, Richard A Lechleiter and Scott G Ginn. View institutional ownership trends. How do I buy shares of Amedisys? Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AMED) was last updated on 5/21/2024 by MarketBeat.com Staff From Our Partners4 Cryptos BETTER than BitcoinTrue Market Insiders[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsNext President (Not Trump. Not Biden.)The Freeport SocietyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlaceElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amedisys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.